



Princess Margaret Cancer Centre

Hospitalizations and emergency visits for Ontario breast cancer patients undergoing neoadjuvant chemotherapy with pembrolizumab

Dr Gary Ko, MSc, MD

April 25, 2025

Background



Neoadjuvant chemotherapy (NAC) regimens containing pembrolizumab (Pembro) are increasingly used for triple negative breast cancer (BC) treatment



In the **KEYNOTE-522** trial, 35% of patients receiving Pembro with chemotherapy experienced immune-mediated adverse events (iRAEs)




iRAEs have the potential of increasing healthcare utilization

- ↑ emergency department (ED) visits
- ↑ hospitalizations

Objective

To assess the rates of hospitalization and ED visits for BC patients undergoing NAC with pembrolizumab, anti-HER2 agents, or chemotherapy alone in Ontario, Canada.

Methods




Statistical analysis: Proportions and Logistic Regression Analysis



Results

Apr 1, 2022 - Aug 31, 2023

- 1301 newly diagnosed BC patients
 - Median age of 52 (44 - 62)
 - 94.7% with no prior comorbidities





Results




During NAC patients receiving Pembro had significantly higher rates of ED visits & hospitalizations, no significant differences were observed post-operatively

Results



Conclusion



Thank you

 gary.ko@uhn.ca

 <https://www.tulincilmd.ca/tictoc>



Team



Dr. Tulin Cil
Principal Investigator



Dr. Toni Zhong
Co-Principal Investigator



Dr. Antoine Eskander
Co-Principal Investigator



Dr. Gary Ko
Project Director

